市場調查報告書
商品編碼
1371987
2030 年腦監測市場預測:按設備、配件、可用性、醫療狀況、最終用戶和地區進行的全球分析Brain Monitoring Market Forecasts to 2030 - Global Analysis By Device (Type, Procedure and Other Devices), Accessories, Usability, Medical Condition, End User and By Geography |
根據 Stratistics MRC 的數據,2023 年全球腦監測市場規模將達到 68 億美元,預計到 2030 年將達到 120 億美元,預測期內年複合成長率為 8.5%。
大腦監測方法旨在獲取有關大腦的電、動態、代謝和解剖學特徵的資料,以幫助診斷、治療、研究和理解許多神經系統疾病和失調。腦電圖(EEG)、腦磁圖(MEG)、功能性磁振造影(fMRI)、近紅外線光光譜(NIRS)、正子斷層掃描(PET)和其他非侵入性或微創技術只是其中的一個例子。許多非侵入性或微創技術用於大腦監測技術。
根據世界衛生組織資料,截至2019年9月,全球約有5,000萬人罹患失智症,每年新增近1,000萬例失智症病例。它是世界各地老年人殘疾和依賴的主要原因之一。
隨著腦部監測技術的快速發展,小工具的準確性、清晰度和效用都提高了。 EEG、MEG、fMRI、NIRS 和其他技術的改進正在開發更複雜、更可靠的監測系統。此外,顱內壓升高是未來腦損傷的關鍵要素,使得 ICP檢測成為腦外傷後頭部影像的重要組成部分。這些發展吸引了學者和醫療保健專業人士,並推動了業務成長。
阻礙全球大腦監測市場成長的另一個挑戰是缺乏具有操作大腦監測設備所需專業知識的人力資源。全球腦監測市場面臨的主要挑戰之一是缺乏高技能和受過教育的工人,限制了該行業在新興市場和發展中國家的成長。因此,全球範圍內對高技能和訓練有素的工人的需求不斷增加。
非洲大陸巨大的人口老化導致了與老齡化相關的神經系統疾病的流行。腦監測技術可以協助早期發現和監測認知能力下降,支持醫療專業人員制定個人化治療計畫並提示治療。隨著年齡的進行性,進行性神經系統疾病變得更加常見。此外,鐮狀細胞性貧血和心臟異常等新疾病的發生頻率正在增加,推動了市場的擴張。
缺乏必要的醫療基礎設施、高昂的醫療成本以及植入應用的安全問題都可能成為大腦監測設備市場擴張的要素。這些設備可能很難使用,使用這些設備的價格可能很高。產品的採用可能會因報銷程序不足或嚴格的政府法規而受到阻礙。
COVID-19大流行不僅對醫療保健系統產生了重大影響,也對大腦監測設備市場產生了重大影響。由於全球封鎖,神經系統檢查被推遲或取消,這對帕金森氏症和癲癇患者及其獲得治療的機會產生了負面影響。然而,隨著大腦監測服務的恢復和病例的減少,市場預計將從大流行中復甦。
創傷性腦損傷(TBI)預計將成為預測期內最大的領域。 TBI 在全球範圍內的日益患病,導致對這些病例的護理需求很高,並需要廣泛使用大腦監測設備,這正在推動這一領域市場的重要佔有率。Masu。此外,已開發國家增加執行新程序的臨床研究和尖端設備的核准預計將刺激該領域的擴張。
預計醫院領域在預測期內複合年複合成長率最高。大腦監測的複雜過程需要使用醫院常見的高科技和昂貴的設備。儘管醫院比其他最終用戶更有能力承受這些費用,但大腦監測技術仍然給醫療機構帶來了巨大的財務負擔。因此,醫院在該市場類別中佔據最大比例,是腦監測設備的主要用戶。
預計北美在預測期內將佔據最大的市場佔有率。這是由於神經系統疾病的增加、腦監測設備臨床試驗的擴大以及美國醫療保險的便利性。強大的醫療基礎設施、不斷上升的醫療成本和高齡化都是該地區的優勢,也是市場開拓的關鍵促進因素。該地區腦部疾病發生率較高,主要企業不斷推出產品預計將對市場成長產生正面影響。
預計亞太地區在預測期內將維持最高的年複合成長率。由於有利的報銷政策的存在,預計市場將在預測期內大幅擴張,特別是在其他某些地區。該地區擁有強大的醫療基礎設施,並且可能會看到技術進步。隨著監控設備領域的深入研究,市場很快就能購買到具有尖端功能的小工具。
According to Stratistics MRC, the Global Brain Monitoring Market is accounted for $6.8 billion in 2023 and is expected to reach $12.0 billion by 2030 growing at a CAGR of 8.5% during the forecast period. Brain monitoring methods attempt to obtain data on the electrical, hemodynamic, metabolic, or anatomical features of the brain to help with the diagnosis, treatment, study, and comprehension of many neurological illnesses and disorders. Electroencephalography (EEG), magnetoencephalography (MEG), functional magnetic resonance imaging (fMRI), near-infrared spectroscopy (NIRS), positron emission tomography (PET), and other non-invasive or minimally invasive techniques are only a few examples of the numerous non-invasive or minimally invasive techniques used in brain monitoring technology.
According to WHO data, as of September 2019, around 50 million people are affected by dementia globally, with nearly 10 million new cases registered each year. It is one of the major causes of disability and dependency among older people worldwide.
The fast developments in brain monitoring technology have all enhanced the gadgets' accuracy, clarity, and usefulness. Improvements in EEG, MEG, fMRI, NIRS, and other techniques have led to the development of more sophisticated and reliable monitoring systems. Additionally, since increased intracranial pressure is a significant contributor to future brain damage, ICP measurement has become a crucial component of head imaging in the aftermath of brain trauma. These developments attract academics and healthcare specialists, promoting business growth.
Another challenge impeding the growth of the global market for brain monitoring is a paucity of personnel with the requisite expertise to operate brain monitoring equipment. One of the main problems the global brain monitoring market has is a dearth of highly skilled or educated workers, which limits the industry's growth in developing and growing nations. As a result, there is an increase in demand for highly skilled or trained workers on a worldwide level.
Due to the continent's huge geriatric population, age-related neurological illnesses are more prevalent. Brain monitoring technology can support medical professionals in creating individualized treatment plans and speedy therapies by helping in the early detection and monitoring of cognitive loss. Progressive neurological diseases and illnesses are more common as people age. Additionally, the frequency of additional ailments is rising, such as sickle-cell anemia and heart abnormalities, which fuels market expansion.
The lack of essential healthcare infrastructure, high medical costs, and safety concerns with implant applications might all act as inhibitors to the expansion of the market for brain monitoring devices. The equipment is fairly challenging to use, and these devices may be pricey to utilize. Adoption of a product might be hampered by poor reimbursement procedures and onerous governmental rules.
The COVID-19 pandemic had a large effect on the healthcare system, as well as the market for brain monitoring equipment. Due to the worldwide lockdown, neurological examinations were postponed or cancelled, which had an adverse effect on Parkinson's patients as well as those with epilepsy and their access to care. The market is anticipated to rebound from the pandemic's fall, though, when brain monitoring services restarted and cases declined.
The traumatic brain injury (TBI) segment is expected to be the largest during the forecast period. The increasing prevalence of TBIs worldwide, which has resulted in a high demand for the care of these cases and necessitated the extensive use of brain monitoring equipment, is a significant cause behind the substantial share of this market sector. Additionally, it is anticipated that a combination of rising clinical studies for implementing new procedures and rising approvals of the newest gadgets in developed nations would fuel the segment's expansion.
The hospitals segment is expected to have the highest CAGR during the forecast period. The intricate process of brain monitoring necessitates the use of high-tech, pricey equipment that is often found in hospitals. Hospitals are more equipped to tolerate these expenditures than other end-users, but brain monitoring technologies still place a significant financial strain on healthcare institutions. Therefore, hospitals account for the greatest proportion of this market category and are the primary users of brain monitoring equipment.
North America is projected to hold the largest market share during the forecast period. This is explained by the rise in neurological disorders, the expansion of brain monitoring device clinical trials, and the accessibility of medical insurance in the US. A strong healthcare infrastructure, increased healthcare spending, and an aging population are all advantages for the area and major market development drivers. A high frequency of brain diseases in the area and ongoing product releases by key companies are also anticipated to positively affect market growth.
Asia Pacific is projected to hold the highest CAGR over the forecast period. Especially in certain other locations, the availability of advantageous reimbursement policies would cause the market to see considerable expansion throughout the projection period. Because of this area's strong healthcare infrastructure, technological advancements are conceivable. The market will soon be able to purchase gadgets with cutting-edge features thanks to significant research in the field of monitoring devices.
Some of the key players in Brain Monitoring Market include: Masimo Corporation, Natus Medical Incorporated, Advanced Brain Monitoring Inc., Nihon Kohden Corporation, Compumedics, Integra Lifesciences Corporation, Medtronic PLC, Koninklijke Philips NV, Nonin Medical Inc., Cadwell Industries Inc., Cerenion Oy, General Electric Company, Siemens Healthcare Private Limited, Yokogawa Electric Corporation, Electrical Geodesics, Koninklijke Philips N. And Advanced Brain Monitoring Inc.
In November 2022, Neurosteer Inc. received FDA clearance for its Neurosteer single-channel EEG brain monitoring platform. This clearance enables the use of Neurosteer's unobtrusive multi-purpose system in a broad range of clinical settings.
In February 2022, Masimo received FDA clearance for its SedLine brain function monitoring for pediatric patients (1-17 years of age) and the SedLine Pediatric EEG Sensor. This clearance expands the potential benefits of SedLine to all patients, one-year-old and above, in the United States.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.